Skip to main content
. Author manuscript; available in PMC: 2010 Jul 2.
Published in final edited form as: Exp Neurol. 2009 Oct 6;223(2):334–346. doi: 10.1016/j.expneurol.2009.09.024

Table 3.

Potential use of cerebrospinal fluid biomarkers in clinical trials.

Application Explanation Time point for use
Clinical diagnosis CSF biomarkers may be valuable in clinical trials on patients with early AD or MCI, to enrich the patient cohort with pure AD cases Baseline evaluation of cases eligible for the trial
Stratification of cases Cases with biomarker evidence of a disturbance in Aβ metabolism or deposition may show a better effect of anti-Aβ disease-modifying drug candidates Baseline evaluation of cases eligible for the trial
Safety monitoring Some cases treated with anti-Aβ drug candidates, such as Aβ immunotherapy, may have adverse events such as meningoencephalitis or vasogenic edema. Baseline evaluation of cases and if a possible adverse event occurs
Theragnostics CSF biomarkers may provide information that the drug has an effect on the biochemistry and pathogenic processes directly in patients with AD Baseline evaluation and at time-points during the trial, including the last week of the trial